How do you approach thoracic treatment volumes for limited-stage small cell lung cancer?

Usually finding a target in LD-SCLC (limited disease, small cell lung cancer) is not a problem. The early days was very much cookie-cutter including both above clavicle regions, both hila and down to diaphragm. When the Intergoup trial was conceived in the late 80's, there was a need to define volumes, and limit dose to esophagus. We did not have PET, while there were in-house treatment planning systems, there were no proprietary ones. In order to permit angled fields, usually parallel opposed o...